CAR-T cell immunotherapy for ovarian cancer: hushing the silent killer

CAR-T cell immunotherapy for ovarian cancer: hushing the silent killer

As the most lethal gynecologic oncological indication, carcinoma of the ovary has been ranked as the 5th cause of cancer-related mortality in women, with a high percentage of the patients being diagnosed at late stages of the disease and a five-year survival of ~ 30%. Ovarian cancer patients convent...

Full description

Bibliographic Details
Main Authors: Fatemeh Nasiri, Khadijeh Farrokhi, Pouya Safarzadeh Kozani, Maral Mahboubi Kancha, Setareh Dashti Shokoohi, Pooria Safarzadeh Kozani
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-12-01
Series:Frontiers in Immunology
Subjects:
cancer immunotherapy
chimeric antigen receptor
ovarian cancer
solid tumors
adoptive cell therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1302307/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1302307/full

Similar Items